Preliminary population pharmacokinetics supports phase II dose selection for masked anti-PD-L1 antibody CX-072.

3602Background: PROBODY therapeutics (Pb-Tx) are antibody prodrugs designed to reduce off-tumor, on-target toxicities. The mask inhibits Pb-Tx binding in the periphery yet can be removed by tumor-a...